{"transactions":[{"id":1509238,"issuer":{"id":7454,"kind":"organization","name":"BriaCell Therapeutics Corp."},"owners":[{"id":90829,"kind":"person","name":"Lustig Marc","position":1,"cik":"0001940908","reported_name":"Lustig Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrants","published_at":"2024-05-20T16:00:14.000Z","date":"2024-05-14","kind":"purchase","planned":false,"acquired":true,"shares":902935,"ownership":{"direct":false,"nature":"By L5 Capital Inc."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common shares and warrants reported on this Form 4 were purchased by L5 Capital Inc. in an offering at a combined purchase price of $2.215 per common share and accompanying warrant, for an aggregate purchase price of $2,000,000 pursuant to a securities purchase agreement dated May 14, 2024. The warrants will be exercisable six months from the date of issuance at an exercise price of $2.11 and will expire on the five year anniversary of the initial exercise date. L5 Capital Inc. is controlled by the Reporting Person, Marc Lustig, a director of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The common shares and warrants reported on this Form 4 were purchased by L5 Capital Inc. in an offering at a combined purchase price of $2.215 per common share and accompanying warrant, for an aggregate purchase price of $2,000,000 pursuant to a securities purchase agreement dated May 14, 2024. The warrants will be exercisable six months from the date of issuance at an exercise price of $2.11 and will expire on the five year anniversary of the initial exercise date. L5 Capital Inc. is controlled by the Reporting Person, Marc Lustig, a director of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The common shares and warrants reported on this Form 4 were purchased by L5 Capital Inc. in an offering at a combined purchase price of $2.215 per common share and accompanying warrant, for an aggregate purchase price of $2,000,000 pursuant to a securities purchase agreement dated May 14, 2024. The warrants will be exercisable six months from the date of issuance at an exercise price of $2.11 and will expire on the five year anniversary of the initial exercise date. L5 Capital Inc. is controlled by the Reporting Person, Marc Lustig, a director of the Issuer."}],"balance_after":902935,"derivative":{"exercise_price":2.11,"underlying":"Common Stock","underlying_shares":902935},"source":{"system":"sec-edgar","filing":"0001493152-24-020660","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1940908/000149315224020660/ownership.xml","form_type":"4"}},{"id":1509237,"issuer":{"id":7454,"kind":"organization","name":"BriaCell Therapeutics Corp."},"owners":[{"id":90829,"kind":"person","name":"Lustig Marc","position":1,"cik":"0001940908","reported_name":"Lustig Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2024-05-20T16:00:14.000Z","date":"2024-05-14","kind":"purchase","planned":false,"acquired":true,"shares":902935,"price":2.215,"value":2000001.025,"ownership":{"direct":false,"nature":"By L5 Capital Inc."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The common shares and warrants reported on this Form 4 were purchased by L5 Capital Inc. in an offering at a combined purchase price of $2.215 per common share and accompanying warrant, for an aggregate purchase price of $2,000,000 pursuant to a securities purchase agreement dated May 14, 2024. The warrants will be exercisable six months from the date of issuance at an exercise price of $2.11 and will expire on the five year anniversary of the initial exercise date. L5 Capital Inc. is controlled by the Reporting Person, Marc Lustig, a director of the Issuer."}],"balance_after":2542935,"source":{"system":"sec-edgar","filing":"0001493152-24-020660","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940908/000149315224020660/ownership.xml","form_type":"4"}}]}